title: Schedule-Dependent Effect of Epigallocatechin-3-Gallate (EGCG) with Paclitaxel on H460 Cells.
abstract: BACKGROUND
  Epigallocatechin-3-gallate (EGCG), a major biologically active component of green tea, has anti-cancer activity in human and animal models. We investigated the schedule-dependent effect of EGCG and paclitaxel on growth of NCI-H460 non-small cell lung cancer cells.
  
  
  METHODS
  To investigate the combined effect of EGCG (E) and paclitaxel (P), combination indices (CIs) were calculated, and cell cycle analysis was performed. For the effect on cell apoptosis, western blot analysis was also performed.
  
  
  RESULTS
  CI analysis demonstrated that both concurrent and sequential E → P treatments had antagonistic effects (CIs >1.0), but sequential P → E had synergistic effects (CIs <1.0), on the growth inhibition of NCI-H460 cells. In the cell cycle analysis, although paclitaxel induced G2/M cell cycle arrest and increased the sub-G1 fraction, concurrent EGCG and paclitaxel treatments did not have any additive or synergistic effects compared with the paclitaxel treatment alone. However, western blot analysis demonstrated that sequential P → E treatment decreased the expression of Bcl-2 and procaspase-3 and increased poly(ADP-ribose) polymerase (PARP) cleavage; while minimal effects were seen with concurrent or sequential E → P treatments.
  
  
  CONCLUSIONS
  Concurrent or sequential E → P treatment had opposite effects to P → E treatment, where P → E treatment showed a synergistic effect on growth inhibition of NCI-H460 cells by inducing apoptosis. Thus, the efficacy of EGCG and paclitaxel combination treatment seems to be schedule-dependent.
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
authors.forename: Sunghoon
authors.initials: S
authors.lastname: Park
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
authors.forename: Joo-Hee
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
authors.forename: Yong Il
authors.initials: YI
authors.lastname: Hwang
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
authors.forename: Ki-Suck
authors.initials: KS
authors.lastname: Jung
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
authors.forename: Young Sook
authors.initials: YS
authors.lastname: Jang
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
authors.forename: Seung Hun
authors.initials: SH
authors.lastname: Jang
keywords: Cell Cycle; Epigallocatechin Gallate; Lung Neoplasms; Paclitaxel
references.citation: J Nutr. 2003 Oct;133(10):3262S-3267S
references.pmid: 14519824
references.citation: Cancer Chemother Pharmacol. 2011 Mar;67(3):637-46
references.pmid: 20495920
references.citation: Lung Cancer. 2006 Jul;53(1):13-21
references.pmid: 16713012
references.citation: Prev Med. 1997 Nov-Dec;26(6):769-75
references.pmid: 9388788
references.citation: Biochem Pharmacol. 2011 Dec 15;82(12):1807-21
references.pmid: 21827739
references.citation: Int J Cancer. 1999 Oct 8;83(2):151-6
references.pmid: 10471519
references.citation: Int J Cancer. 1997 Jan 27;70(3):255-8
references.pmid: 9033623
references.citation: Int J Cancer. 2005 Apr 20;114(4):513-21
references.pmid: 15609335
references.citation: Toxicol Lett. 2004 Apr 15;150(1):43-56
references.pmid: 15068824
references.citation: J Natl Cancer Inst. 1993 Jul 7;85(13):1038-49
references.pmid: 8515490
references.citation: Clin Cancer Res. 2004 Dec 1;10(23):7994-8004
references.pmid: 15585635
references.citation: Gynecol Oncol. 2004 Sep;94(3):760-8
references.pmid: 15350370
references.citation: Int J Oncol. 2008 Jan;32(1):113-20
references.pmid: 18097549
references.citation: Jpn J Clin Oncol. 1993 Jun;23(3):186-90
references.pmid: 8350491
references.citation: Biol Pharm Bull. 2008 Jan;31(1):79-84
references.pmid: 18175946
references.citation: J Natl Cancer Inst. 1994 Jun 1;86(11):855-8
references.pmid: 8182766
references.citation: Nature. 1997 Jun 5;387(6633):561
references.pmid: 9177339
references.citation: J Clin Oncol. 1999 Mar;17(3):1061-70
references.pmid: 10071301
references.citation: Int J Cancer. 1999 Jan 29;80(3):413-6
references.pmid: 9935183
references.citation: Biochem Biophys Res Commun. 2007 Aug 17;360(1):233-7
references.pmid: 17585882
references.citation: Leuk Res. 1991;15(11):1059-66
references.pmid: 1961009
references.citation: Crit Rev Food Sci Nutr. 2003;43(1):89-143
references.pmid: 12587987
references.citation: Jpn J Cancer Res. 1990 Nov;81(11):1101-8
references.pmid: 2125036
references.citation: Int J Cancer. 2008 Sep 1;123(5):1005-14
references.pmid: 18546267
references.citation: Cancer Chemother Pharmacol. 2005 Jan;55(1):33-8
references.pmid: 15309507